WEBULL
News
CASI
1.090
+11.42%
0.112
Weekly Report: what happened at CASI last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at CASI last week (1117-1121)?
Weekly Report · 11/24 10:37
CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman
Reuters · 11/19 14:00
Weekly Report: what happened at CASI last week (1110-1114)?
Weekly Report · 11/17 10:38
CASI Pharmaceuticals Reports Q3 2025 Results Amid Nasdaq Delisting Appeal
TipRanks · 11/14 22:25
CASI Pharmaceuticals GAAP EPS of -$0.67, revenue of $3.07M
Seeking Alpha · 11/14 21:48
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Reuters · 11/14 21:17
CASI Pharmaceuticals Reports Third Quarter Revenue of $3.1 Million and Net Loss of $10.9 Million
Reuters · 11/14 21:05
CASI PHARMACEUTICALS Q3 REVENUE USD 3.1 MILLION
Reuters · 11/14 21:05
CASI PHARMACEUTICALS INC- RECEIVES & APPEALS DELISTING DETERMINATION FROM NASDAQ
Reuters · 11/10 22:43
CASI Pharmaceuticals Appeals Nasdaq Delisting Determination
TipRanks · 11/10 22:27
CASI Pharmaceuticals Receives Nasdaq Delisting Notification
Benzinga · 11/10 21:19
CASI Pharmaceuticals appeals NASDAQ delisting determination
Seeking Alpha · 11/10 21:09
Weekly Report: what happened at CASI last week (1103-1107)?
Weekly Report · 11/10 10:35
CASI Pharmaceuticals Joins Guggenheim Healthcare Innovation Conference
Reuters · 11/04 14:00
CASI Pharmaceuticals To Present Phase 1 CID-103 Data In Immune Thrombocytopenia At ASH 2025
Benzinga · 11/03 14:15
CASI Pharmaceuticals to Present Phase 1 CID-103 ITP Trial Results at ASH 2025
Reuters · 11/03 14:03
Weekly Report: what happened at CASI last week (1027-1031)?
Weekly Report · 11/03 10:35
CASI Pharmaceuticals Advances CID-103 in Promising ITP Study
TipRanks · 10/27 18:25
More
Webull provides a variety of real-time CASI stock news. You can receive the latest news about Casi Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.